Sequencing Of Agents And Combination Therapy In Castrate Resistant Prostate Cancer
AUAUniversity17 Loka 2019

Sequencing Of Agents And Combination Therapy In Castrate Resistant Prostate Cancer

Co-Host: Maxwell Meng, MD At the conclusion of these activities, participants will be able to: 1. Identify treatments for non-metastatic and metastatic CRPC and describe the proper order for their administration. 2. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy. 3. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC. CME Available: auau.auanet.org/node/26067 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Jaksot(422)

Incorporating New IO Therapies - How to Properly Administer IO Therapies in an Infusion Suite

Incorporating New IO Therapies - How to Properly Administer IO Therapies in an Infusion Suite

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

29 Loka 201837min

Immuno-Oncology: A Focus on Bladder Cancer

Immuno-Oncology: A Focus on Bladder Cancer

Immuno-Oncology: A Focus on Bladder Cancer is the second in the 4-part series. Topics will include "non muscle invasive disease" and "muscle invasive disease" as well as "clinical trial evidence" and ...

24 Loka 201854min

AUA2018 Residents Forum: Public Policy and Advocacy in Urology: A Primer for Residents

AUA2018 Residents Forum: Public Policy and Advocacy in Urology: A Primer for Residents

Speakers: Christopher M. Gonzalez, MD, MBA James M. Dupree, MD, MPH

22 Loka 201817min

Incorporating New IO Therapies - Managing Patient Side Effects

Incorporating New IO Therapies - Managing Patient Side Effects

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

19 Loka 201830min

Immuno - Oncoloy: A New Class Of Drugs

Immuno - Oncoloy: A New Class Of Drugs

Immuno-Oncology: A New Class of Drugs is the first in the 4-part series. Topics will include "Tumor Immunotherapy", "Immunotherapy Drug Availability and Mechanisms of Action", "Vaccines", "Monoclonal ...

10 Loka 201842min

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer

Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New is the third podcast in a 4-part series. Topics will include "Manipulating the Androgen Axis: Androgen Biosynthe...

8 Loka 201856min

Incorporating New IO Therapies - Biomarkers

Incorporating New IO Therapies - Biomarkers

To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of ...

4 Loka 201829min

Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment

Castration-Resistant Prostate Cancer (CRPC) Guideline Amendment

To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation are producing a serie...

28 Syys 201851min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
psykopodiaa-podcast
voi-hyvin-meditaatiot-2
rss-narsisti
rss-niinku-asia-on
adhd-podi
rss-liian-kuuma-peruna
aamukahvilla
psykologia
rss-valo-minussa-2
rss-vapaudu-voimaasi
kesken
rss-koira-haudattuna
aloita-meditaatio
dear-ladies
esa-saarinen-filosofia-ja-systeemiajattelu
ihminen-tavattavissa-tommy-hellsten-instituutti
leveli
rss-luonnollinen-synnytys-podcast
filocast-filosofian-perusteet